Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hyaluronan-binding extracellular matrix proteins, collectively known as hyaladherins, are a diverse group of proteins that specifically interact with hyaluronan (HA), a major non-sulfated glycosaminoglycan of the extracellular matrix (Day & Prestwich, 2002, Journal of Biological Chemistry). This group includes structural components like the lecticans (aggrecan, versican, neurocan, and brevican), cell surface receptors such as CD44 and RHAMM, and secreted proteins like TSG-6 and link proteins (Yamaguchi, 2000, Cell and Molecular Life Sciences). These proteins play critical roles in maintaining the structural integrity of the extracellular matrix, regulating cell adhesion, and mediating signaling pathways involved in cell proliferation and migration (Turley et al., 2002, Journal of Biological Chemistry). In pathological states, the interaction between HA and its binding proteins is often dysregulated, contributing to tumor progression, chronic inflammation, and fibrotic diseases (Jiang et al., 2011, Physiological Reviews). Therapeutic strategies targeting these interactions include monoclonal antibodies against specific receptors like CD44, small molecule inhibitors of HA synthesis, and enzymatic degradation of the HA matrix using hyaluronidases (Hingorani et al., 2018, Journal of Clinical Oncology). Because these proteins are ubiquitous in connective tissues, therapeutic development must carefully balance efficacy against the risk of systemic matrix instability and impaired physiological tissue repair (Knudson & Knudson, 2003, Birth Defects Research).
Therapeutic strategies involve the competitive inhibition of hyaluronan binding to receptors like CD44, the enzymatic depletion of the hyaluronan substrate to collapse the protective extracellular matrix, or the inhibition of hyaluronan synthases to reduce the overall density of the hyaluronan-rich microenvironment.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyaluronan-binding extracellular matrix protein (HABP) (HABP).